Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk Progression 60% Time to viral- 9% primary Time to viral- (b) 9% primary Atipornwanich et al. NCT04303299 Favipiravir RCT LATE Is late treatment with favipiravir+combined treatments beneficial for COVID-19? RCT 200 patients in Thailand Trial compares with oseltamivir, results vs. placebo may differ Lower progression with favipiravir+combined treatments (p=0.0085) Atipornwanich et al., SSRN Electronic J., doi:10.2139/ssrn.3936499 Favors favipiravir Favors oseltamivir
Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and Hydroxychloroquine for the Treatment of COVID-19: A Randomized Controlled Trial (FIGHT-COVID-19 Study)
Atipornwanich et al., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, NCT04303299 (history)
Atipornwanich et al., Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, High-Dose Oseltamivir, and.., SSRN Electronic Journal, doi:10.2139/ssrn.3936499, NCT04303299
Oct 2021   Source   PDF  
  All Studies   Meta
RCT 200 moderate/severe patients in Thailand, showing significantly lower progression with favipiravir vs. oseltamivir. NCT04303299 (history).
risk of death, 23.1% lower, RR 0.77, p = 0.66, treatment 10 of 100 (10.0%), control 13 of 100 (13.0%), NNT 33, favipiravir arms vs. oseltamivir arms.
risk of progression, 60.0% lower, RR 0.40, p = 0.009, treatment 10 of 100 (10.0%), control 25 of 100 (25.0%), NNT 6.7, favipiravir arms vs. oseltamivir arms.
time to viral-, 8.7% lower, relative time 0.91, p = 0.43, treatment mean 9.5 (±5.0) n=50, control mean 10.4 (±6.3) n=50, HCQ arms, primary outcome.
time to viral-, 8.9% lower, relative time 0.91, p = 0.34, treatment mean 10.2 (±4.6) n=50, control mean 11.2 (±5.7) n=50, non-HCQ arms, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Atipornwanich et al., 5 Oct 2021, Randomized Controlled Trial, Thailand, peer-reviewed, 16 authors, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with lopinavir/ritonavir or duranivir/ritonavir/HCQ) - results of individual treatments may vary, trial NCT04303299 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Various combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, 2 high-dose Oseltamivir, and Hydroxychloroquine for the treatment of Covid-19: A 3 randomized controlled trial. (FIGHT-COVID-19 Study) 4 Kriangsak Atipornwanich, M.D. 1,2, Subsai Kongsaengdao, M.D. 1,2, Piyathida 5 Harnsomburana, M.D. 1,2, Rienthong Nanna, M.D. 3, Chatchawan Chtuparisute, M.D. 3, 6 Piamlarp Saengsayan, M.D.4, Kittima Bangpattanasiri, M.D. 4, Weerawat Manosuthi, M.D. 7 5, Narumol Sawanpanyalert, M.D. 6, Attasit Srisubat, M.D. 6, Somchai Thanasithichai, M.D. 8 6, Benchalak Maneeton, M.D. 7, Narong Maneeton, M.D. 7, Chuthamanee Suthisisang, B. 9 Pharm, PhD. 8, Jaturong Pratuangdejkul, B. Pharm, PhD. 8, and Somsak Akksilp, M.D. 2,6 pe er re v iew ed 1 10 Affiliations: 11 1 12 of Public Health, Bangkok, Thailand. 13 2 Department of Medicine, College of Medicine, Rangsit University, Bangkok, Thailand. 14 3 Department of Medicine, Monkutwattana Hospital, Bangkok, Thailand. 15 4 Department of Medicine, Central Chest Institute of Thailand, Nonthaburi, Thailand. 16 5 Department of Infectious Disease, Bamrasnaradura Infectious Disease Institute, 17 Nonthaburi, Thailand. 18 6 Department of Medical Services, Ministry of Public Health, Nonthaburi, Thailand. 19 7 Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, 20 Thailand 21 8 ot tn rin Correspondence: Associate Professor Subsai Kongsaengdao, M.D., Division of Neurology, Department of Medicine, 2 Rajavithi Hospital (Victory Monument), Pr 23 Faculty of Pharmacy, Mahidol University, Bangkok Thailand, ep 22 Department of Medicine, Rajavithi Hospital, Department of Medical Services, Ministry 24 Ratchathewi Road, Bangkok 10400, Thailand, Tel +66 22 062 900 Ext 6120, 25 Fax +66 23 545 477, Email FIGHT COVID-19 study {NCT04303299} 1 This preprint research paper has not been peer reviewed. Electronic copy available at: ABSTRACT 27 BACKGROUND 28 Monotherapy with Remdesivir, Favipiravir, Lopinavir-Ritonavir, or Hydroxychloroquine 29 has been evaluated for the treatment of coronavirus disease 2019 (Covid-19). No 30 antiviral agents have yet been shown to be efficacious in terms of viral clearance and 31 reduction of death in moderate to severe Covid-19 in randomized controlled trials. 32 METHODS 33 We conducted an open-label, randomized, controlled trial of various oral combinations 34 of Favipiravir, Lopinavir-Ritonavir, Darunavir-Ritonavir, high-dose Oseltamivir, and 35 Hydroxychloroquine in adults who were hospitalized with Covid-19. Ninety patients 36 were randomly assigned to receive either 1) high-dose Oseltamivir and 37 Hydroxychloroquine, 2) Lopinavir-Ritonavir and high-dose Oseltamivir, or 3) Darunavir- 38 Ritonavir, high-dose Oseltamivir, and Hydroxychloroquine, compared to thirty voluntary 39 quarantine patients without antiviral agent for mild Covid-19. In addition, two hundred 40 patients were randomly assigned to receive 1) high-dose Oseltamivir and Lopinavir- 41 Ritonavir, 2) Favipiravir and Lopinavir-Ritonavir, 3) high-dose Oseltamivir and 42 Darunavir-Ritonavir, or 4) Favipiravir and Darunavir-Ritonavir and Hydroxychloroquine 43 for moderate to severe Covid-19. 44 RESULTS 45 A total of 320 patients were enrolled. Those mild Covid-19 patients who received high- 46 dose Oseltamivir and Hydroxychloroquine had a..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop